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Abstract
Background: The European Academy of Allergy and Clinical Immunology
(EAACI) is in the process of developing the EAACI Guidelines on Allergen
Immunotherapy (AIT) for the management of insect venom allergy. To inform
this process, we sought to assess the effectiveness, cost-effectiveness and safety of
AIT in the management of insect venom allergy.
Methods: We undertook a systematic review, which involved searching 15 interna-
tional biomedical databases for published and unpublished evidence. Studies were
independently screened and critically appraised using established instruments.
Data were descriptively summarized and, where possible, meta-analysed.
Results: Our searches identified a total of 16 950 potentially eligible studies; of
which, 17 satisfied our inclusion criteria. The available evidence was limited both in
volume and in quality, but suggested that venom immunotherapy (VIT) could sub-
stantially reduce the risk of subsequent severe systemic sting reactions (OR = 0.08,
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Allergy
95% CI 0.03–0.26); meta-analysis showed that it also improved disease-specific
quality of life (risk difference = 1.41, 95% CI 1.04–1.79). Adverse effects were expe-
rienced in both the build-up and maintenance phases, but most were mild with no
fatalities being reported. The very limited evidence found on modelling cost-effec-
tiveness suggested that VIT was likely to be cost-effective in those at high risk of
repeated systemic sting reactions and/or impaired quality of life.
Conclusions: The limited available evidence suggested that VIT is effective in reduc-
ing severe subsequent systemic sting reactions and in improving disease-specific
quality of life. VIT proved to be safe and no fatalities were recorded in the studies
included in this review. The cost-effectiveness of VIT needs to be established.
Hymenoptera venom allergy is a potentially life-threatening
allergic reaction following a bee, wasp (i.e. paper wasp, yellow
jacket or hornet) or ant (i.e. fire ants) sting. The risk of anaphy-
laxis to hymenoptera stings is greater in adults compared to
children due to increased sting exposure, comorbidities and con-
comitant medication use. Systemic reactions have been reported
in up to 3% of adults, but in less than 1% of children (1, 2).
Symptoms range from large local reactions at the sting site
to mild, moderate and severe systemic reactions. Mild sys-
temic reactions usually manifest as generalized skin symp-
toms including flush, urticaria and angioedema. Typically,
dizziness, dyspnoea and nausea are examples of moderate
reactions, while shock and loss of consciousness, or even car-
diac or respiratory arrest, all define a severe sting reaction.
Seemingly mild reactions can progress into more severe reac-
tions with little warning. The fear of future severe systemic
reactions usually greatly impairs quality of life. Around a
quarter of fatalities from anaphylaxis are caused by venom
allergy (3–5).
Patients are advised to carry an emergency kit comprising
adrenaline (epinephrine), H1-antihistamines and corticos-
teroids depending on the severity of their previous sting reac-
tion(s) (6). The only treatment that can potentially prevent
further systemic sting reactions is venom immunotherapy
(VIT). This may result in long-term clinical benefits and
improved quality of life (7, 8). However, despite these possi-
ble advantages, VIT is still not commonly used by physicians
across all European countries (9). This is likely to reflect
uncertainty about the clinical benefits and risks associated
with the use of VIT, uncertainties about the ethics of mount-
ing further formal experimental studies when VIT is estab-
lished practice in some countries, as well as the practical and
economic implications associated with this treatment.
The European Academy of Allergy and Clinical Immunol-
ogy (EAACI) is in the process of developing guidelines for
AIT. This systematic review is one of five interlinked
evidence syntheses that were undertaken in order to provide
a state-of-the-art synopsis of the current evidence base in
relation to evaluating AIT for the treatment of insect venom
allergy, allergic rhinoconjunctivitis, food allergy, allergic
asthma and allergy prevention (10–14). These reviews will be
used to contribute to and inform the formulation of key
clinical recommendations for subsequent clinical practice
guidelines.
Aims
We assessed the effectiveness, safety and cost-effectiveness of
VIT for the treatment of insect venom allergy.
Methods
The detailed methods for this review have already been
described in our published protocol (10). Here, we provide a
more succinct account of the methods employed.
Search strategy
A highly sensitive search strategy was developed, and vali-
dated study design filters were applied to retrieve all articles
pertaining to the use of VIT for insect venom allergy from
electronic bibliographic databases (Appendix S1). We concep-
tualized the searches to incorporate the four elements below
as shown in Fig. 1.
To retrieve systematic reviews, we used the systematic review
filter developed at McMaster University Health Information
Research Unit (HIRU) (http://hiru.mcmaster.ca/hiru/HIRU_
Hedges_MEDLINE_Strategies.aspx#Reviews). To retrieve ran-
domized controlled trials (RCTs), we applied the Cochrane
highly sensitive search strategy for identifying RCTs in MED-
LINE (15). To retrieve nonrandomized studies, that is
Abbreviations
AAI, Adrenaline auto-injector; AIT, allergen immunotherapy; CBA, controlled before-and-after studies; CCT, controlled clinical trial; CI,
confidence interval; EAACI, European Academy of Allergy and Clinical Immunology; EPOC, Effective Practice and Organisation of Care;
ICER, incremental cost-effectiveness ratio; ITS, interrupted time series; NCCT, nonrandomized controlled clinical trial; NHS, National Health
Service; NICE, National Institute for Health and Care Excellence; OR, odds ratio; PRISMA, Preferred Reporting Items for Systematic
Reviews and Meta-Analyses; PROSPERO, International Prospective Register of Systematic Reviews; QALY, quality-adjusted life year; RCT,
randomized controlled trials; RR, risk ratio; VIT, venom immunotherapy; WAO, World Allergy Organization; WBE, whole-body extract
immunotherapy.
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controlled clinical trials (CCT), controlled before-and-after
(CBA) and interrupted time-series (ITS) studies, we used the
Cochrane Effective Practice and Organisation of Care (EPOC)
filter version 2.4, available on request from the EPOC Group
(16, 17). To retrieve case series, we used the filter developed by
librarians at Clinical Evidence: http://clinicalevidence.bmj.com/
x/set/static/ebm/learn/665076.html.
We searched the following databases: Cochrane Library
including Cochrane Database of Systematic Reviews
(CDSR), Database of Reviews of Effectiveness (DARE),
CENTRAL (Trials), Methods Studies, Health Technology
Assessments (HTA), Economic Evaluations Database (EED),
MEDLINE (OVID), Embase (OVID), CINAHL (Ebsco-
host), ISI Web of Science (Thomson Web of Knowledge),
TRIP Database (www.tripdatabase.com), Clinicaltrials.gov
(NIH web), Clinicaltrialsregister.eu, Current controlled trials
(www.controlled-trials.com) and the Australian and New
Zealand Clinical Trials Registry (http://www.anzctr.org.au).
The search strategy was developed on OVID MEDLINE
and then adapted for the other databases (see Supporting
information). In all cases, the databases were searched from
inception to 31 October 2015. Additional references were
included through searching the references cited by the identi-
fied studies, and unpublished work and research in progress
was identified through discussion with experts in the field
(see Supporting information). We invited a panel of interdis-
ciplinary external experts in the field from different regions
to add to the list of included studies by identifying additional
published and unpublished papers they are aware of and
research in progress (Appendix S2). There were no language
restrictions employed; where possible, all relevant literature
was translated into English.
Inclusion criteria
Patient characteristics
We were interested in identifying studies conducted on
patients of any age with a physician-confirmed diagnosis of
systemic sting reaction to a venom sting from bees, wasps
(i.e. paper wasp, yellow jacket or hornet) or fire ants.
Interventions of interest
We considered VIT using different products (purified and
nonpurified, aqueous or depot IT) and different treatment
protocols (conventional, cluster, rush and ultra-rush) (18)
administered through the subcutaneous (SCIT) or sublingual
(SLIT) routes.
Comparators
We were interested in studies comparing VIT with placebo or
no treatment (i.e. the natural course of the disease).
Study designs
Systematic reviews of RCTs and RCTs were used to inves-
tigate effectiveness; health economic analyses were used to
assess cost-effectiveness; and systematic reviews, RCTs and
case series, with a minimum of 300 patients, were used to
assess safety. We appraised the evidence by looking at
higher levels of evidence such as systematic reviews and/or
meta-analyses of RCTs, together with individual RCTs.
However, as we were expecting to find only a limited
number of RCTs, we also searched for and included
quasi-RCTs (i.e. nonrandomized controlled clinical trials
(CCTs), controlled before-and-after (CBA) studies and
interrupted time-series (ITS) analyses). Given the high
inherent risk of bias in making inferences from quasi-
RCTs, our main conclusions in relation to effectiveness
have been based on the findings of systematic reviews and
RCTs; findings from the quasi-RCTs have only been used
to guide suggestions on which areas need to be prioritized
in future research (19).
Our exclusion criteria were as follows: narrative reviews,
discussion papers, nonresearch letters and editorials, animal
studies, before–after studies, qualitative studies and case
series (involving less than 300 patients).
Outcomes
Primary.
• Our primary outcome measure of interest was short- and
long-term efficacy assessed by tolerated sting challenge or
Condition
• Insect venom allergy
• Patients with systemic 
sting reactions to ire 
ants; bees and bumble
bees and paper wasps and
wasps.
Interventions
• VIT: subcutaneous 
immunotherapy (SCIT) 
and sublingual 
immunotherapy (SLIT)
• Different products: 
puriied and nonpuriied 
aqueous, depot 
• Treatment protocols: 
conventional, cluster, rush 
and ultra-rush
Outcomes
• Eficacy/effectiveness: 
tolerated sting challenge 
or ield sting 
• Disease speciic quality of 
life
• Cost-effectiveness
• Safety
Study designs
• Systematic review +/-
meta-analysis 
• Randomized controlled 
trial (RCT) to assess 
effectiveness
• Quasi-RCTs
• Non-randomized 
controlled clinical trials 
(CCT)
• Controlled before–after 
(CBA) studies
• Interupted time-series 
studies(ITS) 
• Cost-effectiveness or cost-
utility analysis to assess 
health economics
• Case series (>300 patients) 
to assess safety
Figure 1 Conceptualization of systematic review of allergen immunotherapy for insect venom allergy (10).
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field sting; long-term was defined as sustained clinical effi-
cacy after discontinuation of VIT.
Secondary. Our secondary outcome measures of interest were
as follows:
• Assessment of disease-specific quality of life
• Safety as assessed by local and systemic reactions in
accordance with the World Allergy Organization’s
(WAO) grading system of side-effects (20, 21)
• Health economic analysis from the perspective of the
health system/payer.
Study selection
All references were uploaded into the systematic review soft-
ware DistillerSR and de-duplication was undertaken. Study
titles were independently checked by two reviewers (SD and
HZ) according to the above selection criteria and categorized
as included, not included or unsure. For those papers in the
unsure category, we retrieved the abstract and re-categorized
studies as above. Any discrepancies were resolved through
discussion and, when necessary, a third reviewer arbitrated
(AS). Full-text copies of all potentially relevant studies were
obtained and their eligibility for inclusion independently
assessed. Studies that did not fulfil all of the inclusion criteria
were excluded.
Quality assessment strategy
Quality assessments were independently carried out on each
study by two reviewers (SD and HZ) using the relevant ver-
sion of the Critical Appraisal Skills Programme (CASP) qual-
ity assessment tool for systematic reviews and health
economic evaluations (22). We assessed the risk of bias of
experimental studies using the criteria suggested by the
Cochrane EPOC Group (23). RCTs, CCTs and CBAs were
assessed for generation of allocation sequence, concealment
of allocation, baseline outcome measurements, baseline char-
acteristics, incomplete outcome data, blinding of outcome
assessor, protection against contamination, selective outcome
reporting and other risks of bias using the Cochrane Risk of
Bias tool (24). For ITS designs, we planned to assess the inde-
pendence of the intervention from secular trends, the prespec-
ified shape of the intervention and whether the intervention
may have had an impact on data collection. These method-
ological assessments drew on the principles incorporated into
the Cochrane EPOC guidelines for assessing intervention
studies (25). We used the quality assessment form produced
by the National Institute for Health and Care Excellence
(NICE) to critically appraise case series (26). Any discrepan-
cies were resolved by discussion or, if agreement could not be
reached, by arbitration by the third reviewer (AS).
Analysis, data synthesis and reporting
Data were independently extracted onto a customized data
extraction sheet in DistillerSR by two reviewers (SD or AK
and HZ), and any discrepancies were resolved. To minimize
the risk of bias, reviewers were not involved in the quality
appraisal of their own studies.
A descriptive summary with data tables was produced to
summarize the literature. A narrative synthesis of the data
was undertaken. Where possible, and appropriate, meta-ana-
lysis was undertaken using random-effects modelling using
Stata (version 14) (15).
Sensitivity and subgroup analyses and assessment for
publication bias
We planned to undertake sensitivity analyses by comparing
the summary estimates obtained by excluding studies judged
to be at high risk of bias, but were unable to do this because
of insufficient data.
We planned to perform the following subgroup analyses, but
were unable to undertake any of these due to insufficient data:
• Children (5–11 years) vs adolescents (12–17 years) vs
adults (≥18 years)
• Conventional vs cluster vs rush vs ultra-rush protocols in
SCIT
• Conventional in SLIT vs SCIT
• Three vs five years of treatment
• Different allergen doses (50 lg vs 100 lg vs 200 lg of
maintenance VIT)
• Bee vs wasp vs fire ant venom
• Patients with and without co-existent mast cell disorders
(27).
We were unable to assess publication bias through the cre-
ation of funnel plots due to the small number of studies, but
were able to use Begg’s rank correlation test (28).
Registration and reporting
This review has been registered with the International
Prospective Register of Systematic Reviews (PROSPERO):
http://www.crd.york.ac.uk/prospero/. The registration num-
ber is CRD42016035374. The Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) checklist
was used to guide the reporting of the systematic review:
http://www.prisma-statement.org/ (Appendix S3; see Support-
ing information).
Results
Overview of results
Our searches identified a total of 16 950 potentially eligible
studies; of which, 17 satisfied our eligibility criteria and were
therefore included in this review (see Fig. 2). The key charac-
teristics and main findings of all included studies are detailed
in Table 1 and the quality assessment of these studies is sum-
marized in Tables 2–4. The main findings are discussed in
more detail below.
Of the 17 included articles, five were systematic reviews (29–
33); two of these systematic reviews undertook meta-analyses
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(29, 33). The remaining 12 studies comprised five RCTs (34–
38), three CBAs (39–41) and four case series (42–45).
Four of the systematic reviews looked at the effectiveness
of VIT (29–31, 33), two at safety (29, 32) one at cost-effec-
tiveness (31) and one at disease specific quality of life (29).
Two of the RCTs looked at both effectiveness and disease-
specific quality of life-related issues in adults (35, 36). Two
RCTs looked at the effectiveness of VIT in children (37, 38);
and a further RCT studied both children and adults (33).
One CBA solely focused on the safety of rush VIT protocol
in adults (40), a second CBA looked at the long-term follow-
up of children following VIT (39), and the third looked at
the effect of VIT on anaphylactic sting reactions (41).
Finally, four case series studies investigated safety considera-
tions (42–45). All of the primary studies included in this
review investigated SCIT.
Effectiveness of VIT as judged by the risk of systemic sting
reactions
Twelve studies looked at the effectiveness of VIT. Four of
these were systematic reviews, all of which were assessed to
be of high quality (29–31, 33). The remaining studies were
RCTs (n = 5) (34–38) and CBAs (n = 3) (39–41).
Systematic reviews
Boyle et al.’s (29) systematic review included six RCTs and
one quasi-RCT. Three of the RCTs studied in this review
also satisfied our eligibility criteria and these are therefore
considered in detail below (34, 37, 38). The others were
excluded because they did not meet our inclusion criteria.
These included Brown et al. (46), which looked at the jack
jumper ant, which was not an insect of interest in the proto-
col; Oude Elberink et al. (47), which focussed on the burden
of treatment of carriage of an adrenaline (epinephrine) auto-
injector compared to VIT, which was not an outcome of
interest; and Golden et al. (48) and Severino et al. (49),
which both included patients who had experienced large
local reactions rather than a systemic reaction to an insect
sting.
The primary outcome of interest in Boyle et al. (29) was
systemic reaction rates to a ‘field’ or a challenge sting in
patients during the follow-up period of VIT treatment. The
review concluded that VIT was effective in preventing
Records idenﬁed through 
database searching
N = 16910
Addional records idenﬁed 
through other sources
N = 40
Records aer duplicates removed
N = 15349
Records screened
N = 15349
Records excluded
N = 15217
Full-text arcles assessed 
for eligibility
N = 132
Full-text arcles excluded, 
with reasons
N = 115
Incorrect study design = 54
Incorrect comparator = 30
Incorrect populaon 
studied = 8
Other = 23
Studies included in 
qualitave synthesis
N = 17
5 SRs, 12 Primary studies
Studies included in 
quantave synthesis 
(meta-analysis)
N = 4
Figure 2 PRISMA diagram: allergen immunotherapy for insect venom allergy.
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subsequent systemic reactions to insect stings (risk ratio
[RR] = 0.10, 95% confidence interval (CI) 0.03–0.28). They
also found that VIT prevented large local reactions to a sting
(RR = 0.41, 95% CI 0.24–0.69).
The systematic review conducted by Dhami et al. (30) on
the management of anaphylaxis studied the effectiveness of
VIT in preventing venom-triggered anaphylaxis. This review
included four systematic reviews (29, 31, 33, 50) and 23 indi-
vidual studies of varying quality. It concluded that although
much of the evidence is of a low quality, the evidence did
consistently suggest that VIT can significantly reduce the risk
of systemic reactions in subsequent stings.
The systematic review by Hockenhull et al. (31) concluded
that VIT reduced the likelihood of future systemic reactions.
This review assessed the clinical and cost-effectiveness of a
specific brand of VIT: Pharmalgen (ALK-Abello). The origi-
nal search strategy was to look at the effectiveness of Phar-
malgen (ALK-Abello) vs other non-VIT treatments, but this
had to be modified as no studies were found matching the
original objective; they therefore widened the criteria to
include other forms of Pharmalgen VIT administration pro-
tocols. The quality of trials included in the review was overall
judged to be at high risk of bias. The review concluded that
although the evidence was poor, it suggested that Pharmal-
gen VIT reduced the risk of future systemic reactions.
Watanabe et al. (33) carried out a high-quality systematic
review looking at the effectiveness of VIT in patients who
presented with a systemic reaction to insect stings. Four stud-
ies were included (34, 37, 38, 46) and a meta-analysis was
performed, based on the Schuberth et al. and Valentine et al.
studies, which demonstrated that there was a substantial
reduction in the risk of systemic reactions occurring in chil-
dren treated with VIT following an accidental sting (odds
ratio (OR) = 0.29 (95% CI 0.10 < OR < 0.87)). The other
two studies were judged to be at low risk of bias, but because
of heterogeneity between studies they could not be included
in the meta-analysis. Overall, this systematic review con-
cluded that VIT was effective and should be recommended
for adults with systemic reactions and for children with mod-
erate-to-severe reactions, but not for children who only expe-
rienced cutaneous manifestations of a systemic reaction.
In summary, the evidence from these four systematic
reviews suggests that VIT is effective in reducing subsequent
systemic sting reactions in both children and adults; all four
reviews have, however, highlighted the low quality of evi-
dence that this conclusion is based on.
RCTs
Five RCTs also focussed on the effectiveness of VIT (34–38).
Hunt et al.’s (34) study was a single-blind RCT of 59
patients aged 15–69 years investigating VIT vs whole-body
extract (WBE) immunotherapy vs placebo; it was judged to
be at high risk of bias. After 6–10 weeks of treatment,
patients were randomly selected for a sting challenge. Of the
19 patients receiving VIT, 18 were stung with only one (5%)
systemic reaction. The WBE and placebo groups each had 20
patients, from which 11 (55%) and 12 (60%) patients were
stung, respectively. In both groups, there were seven systemicT
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sting reactions. There were significantly more systemic
reactions to the sting challenge in the WBE and placebo
groups when compared with the VIT group (P < 0.01). There
was no difference in effectiveness between the WBE and pla-
cebo group. The authors concluded that VIT was superior to
both WBE and placebo in preventing further systemic sting
reactions and recommended the use of VIT to prevent life-
threatening systemic sting reactions.
The two Oude Elberink et al. RCTs, which primarily
looked at quality of life, also reported on re-sting rates. In
both studies, they randomized patients to VIT or adrenaline
auto-injector. In the 2002 study, two patients experienced a
re-sting; one patient from the randomized control arm experi-
enced a sting and developed a systemic reaction (1/38) which
required use of an adrenaline auto-injector; one patient in
the VIT group had a re-sting, but did not develop a systemic
reaction. This patient was in the randomized VIT group (35).
In the 2009 study, of 29 patients whose index sting reaction
was confined to systemic cutaneous reactions, five patients
experienced a field sting: three in the VIT group and two in
the adrenaline auto-injector group. None of these five
patients experienced a systemic sting reaction (36).
Schuberth et al. and Valentine et al. both looked at chil-
dren with non-life-threatening sting reactions (37, 38). Both
of these trials were judged to be at moderate risk of bias.
They randomized children to VIT or no-VIT and studied sys-
temic sting reactions to bees and wasps in those experiencing
accidental stings. Schuberth et al. who looked at 181 children
with systemic sting reactions limited to cutaneous manifesta-
tions found no statistical difference in the number of systemic
sting reactions following an accidental sting in the VIT and
no treatment group (35). They further found that no subse-
quent reaction was more severe than the original and in the
no-VIT group of eight systemic reactions only one was as
serious as the original. This led to their conclusion that chil-
dren with primarily cutaneous manifestation to a sting were
unlikely to experience a further systemic reaction following a
re-sting. A total of 242 children were included in the Valen-
tine et al.’s study. Of 45 children who experienced 55 stings,
only one child in the VIT group experienced a systemic reac-
tion to a field sting (1.8% systemic reactions/sting) compared
to seven systemic reactions from 68 stings in 61 children who
did not receive VIT (10.3% systemic reactions/sting) over a
period of 4 years (RR = 0.21, 95% CI 0.03–1.66, P = 0.14)
(36). Both studies concluded that VIT is not indicated in chil-
dren with cutaneous manifestations only.
CBAs
The CBAs by Golden, Pasaoglu and Reisman et al. were all
judged to be at moderate risk of bias (39–41). Golden et al.
assessed the long-term effectiveness of VIT compared to no-
VIT in preventing systemic sting reactions in 512 children
(aged 10–20) after an average of 3.5 years of VIT treatment.
They found a prolonged benefit in the treatment group as
the VIT group experienced less systemic sting reactions (two
of 64 patients, or 3%) than the untreated patients (19 of 111
patients, or 17%; P = 0.007) (39). This study suggested that
VIT was effective in children with moderate-to-severe
reactions, but that VIT was not recommended in children
who experienced mild reactions.
In contrast, the CBA by Pasaoglu et al. (40) looked at the
effectiveness of a seven-day rush protocol of VIT in 18
patients. Seven received bee VIT, seven yellow jacket VIT
and four were controls. Of the 14 patients who received VIT,
two experienced accidental stings (including a bee keeper
who had multiple stings). No systemic sting reactions
occurred. They concluded that a seven-day rush protocol is
effective.
The CBA by Reisman et al. (41) looked at children and
adults with anaphylaxis to stings from honeybee or yellow
jacket or bald-faced hornets or paper wasps. They looked at
three groups and their subsequent reactions to accidental
stings over a seven-year period: those who had VIT, those
who started VIT, but stopped prematurely and those without
VIT. The group that took VIT for the recommended dura-
tion (mean 34 months) had 87 re-stings with only two sys-
temic reactions (1%). The group that stopped VIT
prematurely (duration of VIT 1 month to 6.5 years) experi-
enced 61 re-stings with 11 systemic reactions (17%). The
group with no-VIT experienced 40 re-stings with 14 systemic
reactions (35%). They concluded that VIT was almost 100%
protective against subsequent sting-triggered anaphylaxis.
Meta-analysis of the Reisman and Golden et al.’s studies
demonstrated an overall substantial protective effect of VIT
against subsequent systemic reactions (OR = 0.08, 95% CI
0.03–0.26; see Fig. 3).
Impact on disease-specific quality of life
Systematic reviews
The systematic review by Boyle et al. (29) drew on two RCTs
by Oude Elberink et al. (35, 47), the former of which is also
included in this review and discussed below. This systematic
review found that VIT was associated with a significant
improvement in disease-specific quality of life after 1 year of
VIT (RR = 7.11, 95% CI 3.02–16.71).
RCTs
Two RCTs assessed the impact of VIT on disease-specific
quality of life measured using the Vespid allergy Quality of
Life Questionnaire (VQLQ) (35, 36). Both of these studies
looked at patients allergic to yellow jackets. The Oude Elber-
ink et al.’s (36) RCT study looked at the impact on disease-
specific quality of life in patients who had experienced only
cutaneous manifestations of a systemic reaction; patients
were randomized to VIT or an adrenaline auto-injector. The
VQLQ score of patients in the VIT arm improved signifi-
cantly (mean change 0.83 (SD 0.87); P < 0.01), in contrast to
patients randomized to an adrenaline auto-injector whose
scores deteriorated (mean change 0.42 (SD 0.64)), resulting
in an overall risk difference of 1.25 (95% CI 0.63–1.87). The
study suggested that all adults, including those who only had
dermal reactions as a systemic allergic reaction to yellow
jacket stings, should be considered for VIT and sole treat-
ment with an adrenaline auto-injector should be avoided
(36).
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A similar earlier RCT (2002) by the same research team
looked at disease-specific quality of life in patients who had
experienced a systemic reaction after a yellow jacket sting
that was not solely confined to the skin (35). The findings
of this study were confirmed in their 2009 study, whereby
there was a clinically relevant improvement in disease-speci-
fic quality of life in patients treated with VIT. The mean
change in VQLQ score in the group randomized to VIT
was 1.07 (95% CI, 0.68–1.46), and this improvement was
also statistically significant (P < 0.0001) compared with that
seen in the group randomized to the adrenaline auto-injec-
tor, in which this change was –0.43 (95% CI, –0.71 to –
0.16) with a mean difference between the two groups of
1.51 (95% CI, 1.04–1.98). Of every three patients treated
with VIT, two patients experienced a clinically relevant
important improvement in their disease-specific quality of
life. Overall, it was found that 72% of patients benefited
from VIT, this corresponding to a number needed to treat
(NNT) of 1.4. Meta-analysis of these studies demonstrated
an improvement in disease-specific quality of life (1.41, 95%
CI 1.04–1.79; see Fig. 4). The Begg test (P = 0.317) showed
no evidence of publication bias.
Safety
Systematic reviews
The review by Boyle et al. (29) assessed the safety of VIT, six
trials reported on this outcome. They concluded that VIT
carries a small but significant risk of systemic reactions
(RR = 8.16; 95% CI 1.53–43.46). They further looked at 11
observational studies for safety and found that systemic
adverse events occurred in 14.2% of participants treated with
bee venom VIT and 2.8% of those treated with wasp venom
VIT.
The systematic review by Park et al., which was assessed
as of a low quality, looked at identifying the frequency and
types of adverse events associated with different types of bee
venom therapy; in doing so, they included VIT, but also
acupuncture (32). It included 145 studies consisting of 20
RCTs, 79 audits and cohort studies, 33 single case studies
and 13 case series. Two RCTs on VIT were included (35, 47),
one of which we have included in this review (2002), and 63
case series/cohort studies. From 46 VIT case series/cohort
studies, the median incidence of adverse events was 28.9%.
Of these, 50.4% had systemic reactions and 10.0% large local
reactions; 35.8% showed just local reactions and 3.9% had
‘other’ reactions.
RCTs
Of the RCTs included in this review, two reported very lim-
ited information on safety considerations of VIT and this is
included in Table 2 (34, 36).
CBAs
The CBA conducted by Pasaoglu et al. evaluated the safety
of a rush VIT protocol lasting on average 7 days and moni-
tored for local and systemic reactions during both the induc-
tion and maintenance phases of VIT treatment over a one-
year period. The study concluded that rush VIT was safe and
associated with a low risk of systemic reactions (four sys-
temic reactions from a total of 469 injections, this equating
to a 0.85% risk per total number of injections) and that this
treatment approach could therefore be considered for
patients requiring rapid protection such as those with a high
risk of subsequent stings (e.g. bee keepers and their families).
The risk of systemic reaction to VIT was related to the type
of venom used with vespid venom being better tolerated than
bee venom (40).
Case series
Four large case series (i.e. Brehler, Mosbech, Ru€eff and Sto-
evesandt et al.) met our eligibility criteria. The Brehler et al.’s
study looked at the safety implication of shortening the seven-
to nine-day rush protocol to 2 days as well as increasing the
initial dose of venom administered. No anaphylactic reactions
were seen in 1055 VIT treatments in 966 patients; most
adverse events were mild and none needed treatment with
adrenaline. Overall, they concluded the two-day rush protocol
is safe and the risk of systemic reactions is rare when the num-
ber of injections administered is reduced from 20 subcuta-
neous injections to nine (42). The Mosbech et al.’s case series
included 840 patients, was conducted in 10 European coun-
tries and assessed the safety of VIT in both the build-up and
maintenance phases in patients allergic to honeybees, wasps
Study
Reisman 1985a
Golden 2004
0.08 (0.03, 0.26)
0.14 (0.03, 0.63)
0.04 (0.01, 0.20)
Overall (I-squared = 14.7%, p = 0.279)
.009 1 111
OR (95% Cl)
Figure 3 Meta-analysis of CBA studies investigating the effectiveness of VIT on risk of systemic sting reactions (random effects).
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and paper wasps (45). Treatment protocols were not standard-
ized across centres, and conventional, rush and cluster proto-
cols were used. A total of 782 patients received VIT with one
venom and 58 with two venoms, respectively. A total of
26 601 injections were administered and 299 systemic side-
effects occurred (1.2% of injections). Most of these reactions
were mild based on the Mueller grading scale (51) with only
one-third needing treatment. One patient required adrenaline.
Adverse events were more frequent during the dose-increase
phase than during the maintenance phase (mean: 1.9% vs
0.5% of all injections). Other factors were identified that
resulted in an increase in adverse events. These included
female gender, rapid dose-increase regimens and VIT with bee
venom extract. They concluded that systemic side-effects may
occur in up to 20% of patients, but are usually mild.
The Ru€eff et al.’s case series looked at measuring the
severity of reactions according to the Ring and Meßmer (52)
tool during the build-up phase of VIT, which required emer-
gency intervention. They evaluated 680 patients in which
VIT was delivered using the following protocols; conven-
tional, rush and ultra-rush protocols for bee and vespid
immunotherapy. The study identified a number of risk fac-
tors that led to a higher frequency of adverse events requir-
ing emergency intervention during VIT; these included bee
venom immunotherapy and using rush and ultra-rush proto-
cols. The authors concluded that patients receiving bee VIT
warrant closer monitoring than those patients receiving VIT
to other insects (43).
Stoevesandt et al. looked at the incidence of systemic
reactions during 818 build-up cycles (rush five-day or ultra-
rush three-day inpatient treatment protocol), and the sever-
ity of VIT-related anaphylaxis was graded according to the
WAO classification system (20). The data from this study
indicated that rush protocols were safe with very low num-
bers of patients suffering from moderate-to-severe systemic
anaphylaxis (i.e. 673 (82.3%) of 818 documented build-up
cycles were tolerated without complications). However, the
authors acknowledged that due to low numbers of moder-
ate-to-severe anaphylaxis reactions (0.8% of patients in the
total cohort), robust statistical conclusions could not be
drawn (44).
Health economic analysis
We found only one study, the review by Hockenhull et al.
(31), that looked at the economic evaluation of VIT – a
modelling study looking at the cost-effectiveness of VIT for
the treatment of bee and wasp venom allergy. The study
compared VIT with Pharmalgen plus high-dose H1-antihista-
mines plus adrenaline auto-injectors (AAI) vs high-dose H1-
antihistamines plus adrenaline auto-injectors and avoidance
advice only. It found that VIT was not cost-effective in the
general population (incremental cost-effectiveness ratio
(ICERs) of £18 million and £7.6 million per quality-adjusted
life year (QALY) against high-dose H1-antihistamines plus
AAI and avoidance advice only, respectively), but more
effective than other treatment options and cost saving in
patients likely to be stung more than five times per year such
as bee keepers. This one study, despite the fact that it was
based largely on expert opinion and plausible assumptions,
resulted in the suggestion that VIT for bee and wasp venom
allergy is only cost-effective from a UK National Health Ser-
vice (NHS) perspective for very high-risk groups likely to be
exposed to multiple exposures to venom per year such as bee
keepers. The modelling analysis suggests plausible ranges of
exposure to such events to qualify a patient as a member of
a high-risk group and explores a wide range of sensitivity
and scenario analyses to demonstrate the robustness of its
findings.
We were unable to find any primary studies assessing the
cost-effectiveness of VIT for venom allergy.
Discussion
Statement of principal findings
This systematic review has found a modest body of evidence
of moderate quality, which suggests that VIT is effective in
reducing subsequent severe systemic sting reactions in both
children and adults and that this treatment modality can have
a significant beneficial impact on disease-specific quality of life
when compared with carrying an adrenaline auto-injector.
The available data on the safety of VIT suggest that although
Study
Elberink 2002
Elberink 2009
Overall (I-squared = 0.0% p = 0.512)
–1.98 0 1.98
1.41 (1.04, 1.79)
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Figure 4 Meta-analysis of RCTs investigating the effectiveness of VIT on VQLQ (random effects).
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adverse events occurred during both the build-up and mainte-
nance phases, the vast majority were relatively mild with adre-
naline only being needed very infrequently and – importantly
– no fatalities being recorded. We found no primary evidence
on the cost-effectiveness of VIT; the one modelling study
found that VIT would be cost-effective in high-risk groups or
if disease-specific quality of life was taken into consideration.
Strengths and limitations
There are a number of strengths to this systematic review. In
particular, we searched a broad array of databases for pub-
lished and in progress research, and also consulted with a
panel of international experts in an attempt to identify
unpublished evidence. Furthermore, our systematic review
was conducted according to a predefined, published protocol
with no deviations from this (10).
The limitations of this review also need to be considered.
Key here was the limited number of studies identified, despite
the fact that we also included CBAs. The review is further
limited by the low quality of the primary studies. Further-
more, two of the RCTs included in this systematic review
(i.e. Valentine and Schuberth) excluded patients who had
life-threatening systemic reactions to the initial sting – the
group of patients who would be most likely to benefit from
VIT (36, 37). Furthermore, it should be noted that in both of
these studies, the definitive identification of the culprit insect
responsible for the accidental sting was not possible. Thus,
whether the child was stung by the insect responsible for the
index sting which resulted in a systemic reaction was
unknown. This is in contrast to the Hunt trial in which
patients were sting-challenged by the insect they were known
to be allergic to (35). As this review did not include the jack
jumper species of ants, the double-blind placebo-controlled
RCT by Brown et al. (46) could not be included in this
review. This study concluded that VIT significantly reduces
the risk of serious subsequent sting reactions from the jack
jumper ant (P < 0.0001). Only one study assessed the cost-
effectiveness of VIT and this was limited to looking only at
one product and based on an economic modelling analysis
(31). Finally, as with any systematic review, there is the pos-
sibility that we missed some studies.
Interpreting the results of this review in the context of the
wider literature
In undertaking this systematic review, we sought to identify
all relevant previous systematic reviews. Our findings are
broadly in accordance with these previous reviews, namely
that VIT is beneficial, but that this judgement is limited by
the paucity and quality of the relevant evidence base. Guide-
lines for the long-term management of allergic reactions to
venom advocate the use of VIT in patients who have experi-
enced moderate-to-severe systemic reactions (53, 54). In
agreement with our findings, VIT is not recommended in
children whose index reaction was confined to cutaneous
manifestations. SLIT remains an experimental treatment in
VIT; no SLIT studies satisfied our eligibility criteria.
Implications for policy, practice and research
The results of our review indicate that people who experience
moderate-to-severe systemic reactions to venom are likely to
benefit from treatment with VIT. This benefit consists of a
reduction in the frequency and severity of subsequent sys-
temic reactions following future stings and/or a clinically rel-
evant improvement in disease-specific quality of life. We
found very limited evidence on the cost-effectiveness of VIT
for venom allergy which thus needs to be interpreted cau-
tiously; the available evidence, from a single economic mod-
elling study, indicated that VIT is likely to be cost-effective
in patients at high risk of future sting reactions and/or if
quality of life is impaired.
Given the paucity of high-quality evidence uncovered, con-
sideration needs to be given to undertaking high-quality stud-
ies investigating the effectiveness and cost-effectiveness of
VIT. RCTs in both adults and children would be of interest,
but due to the risk of life-threatening reactions in untreated
patients, RCTs may not be considered ethical by some clini-
cians and furthermore they may not be approved by some
ethics committees. It seems unlikely therefore that there will
be further placebo-controlled trials of VIT preparations in
the foreseeable future. As for VIT regimens, at present many
protocols for VIT are used discretionally at treatment centres
with varying build-up and maintenance doses with no defined
duration of treatment. These protocols vary from conven-
tional (12 weeks) to one-day ultra-rush protocols during the
build-up phase. Time taken to reach the maintenance dose
will be dependent on the build-up phase and varies across
centres. Trials should therefore be considered comparing dif-
ferent VIT regimens, doses and durations of VIT. Whether
trials of SLIT for venom allergy are indicated is debated
(55). More standard reporting of VIT-associated adverse
events is needed in order to allow comparison across studies.
Primary studies of cost-effectiveness are also needed.
Conclusions
The limited available evidence suggests that VIT is effective in
reducing subsequent severe systemic sting reactions and in
improving disease-specific quality of life. VIT proved to be safe
and no fatalities were recorded in the studies included in this
review. The cost-effectiveness of VIT needs to be established.
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